Two decades in review: Progress in the treatment of mCRPC

Brandon Bernard, Arun A. Azad, Kim N. Chi

Research output: Contribution to journalArticleResearchpeer-review


Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.

Original languageEnglish
Pages (from-to)18-23
Number of pages6
JournalOncology Exchange
Issue number3
Publication statusPublished - 1 Aug 2014
Externally publishedYes


  • Androgen deprivation therapy
  • Androgen receptor antagonist
  • Bone-targeted therapy
  • Chemotherapy
  • Immunotherapy
  • Metastatic castration-resistant prostate cancer
  • Predictive biomarker
  • Radiopharmaceutical

Cite this